Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders

Trial Profile

Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2013

At a glance

  • Drugs Cytarabine (Primary) ; Etoposide (Primary) ; Vorinostat (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Apr 2013 Planned End Date changed from 1 Aug 2010 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 27 Oct 2009 Status changed from suspended to recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top